# 1 A cross-tissue, age-specific flow cytometry reference for immune cells in the airways and 2 blood of children

- 3 Shivanthan Shanthikumar<sup>1,2,3</sup>, Liam Gubbels<sup>1</sup>, Karen Davies<sup>4</sup>, Hannah Walker<sup>1,2,5</sup>, Anson Tsz
- 4 Chun Wong<sup>1,2</sup>, Jovana Maksimovic<sup>6,7</sup>, Alicia Oshlack<sup>6,7,8</sup>, Richard Saffery<sup>1,2</sup>, Eric Levi<sup>4,9</sup>,
- 5 Sarath C. Ranganathan<sup>1,2,3</sup>, Melanie R. Neeland<sup>1,2</sup>

6 <sup>1</sup> Infection, Immunity and Global Health, Murdoch Children's Research Institute, Parkville, VIC, Australia.

7 <sup>2</sup> Department of Paediatrics, University of Melbourne, Parkville, VIC, Australia.

- 8 <sup>3</sup> Respiratory and Sleep Medicine, Royal Children's Hospital, Parkville, VIC, Australia.
- <sup>4</sup> Otolaryngology, Royal Children's Hospital, Parkville, VIC, Australia.
- <sup>5</sup> Children's Cancer Centre, Royal Children's Hospital, Parkville, VIC, Australia.
- <sup>6</sup> Computational Biology Program, Peter MacCallum Cancer Centre, Parkville, VIC, Australia.
- <sup>7</sup> Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, Australia.
- <sup>8</sup> School of Mathematics and Statistics, University of Melbourne, Parkville, VIC, Australia.
- <sup>9</sup> Clinical Sciences, Murdoch Children's Research Institute, Parkville, VIC, Australia.

### 15 <u>ABSTRACT</u>

16 Respiratory diseases are a common cause of morbidity and hospitalisation for children. 17 Despite this, treatment options are limited and are often ineffective. The development of 18 curative or disease-modifying treatments for children relies on a better understanding of 19 underlying immunity in the early airway. To establish a flow cytometry reference for immune 20 cells in the paediatric airway, we analysed 178 samples from 66 children aged between 1-15 21 years. This included five tissues of the upper (nasal brushings, palatine tonsils, adenotonsil) and lower (bronchial brushings, bronchoalveolar lavage (BAL)) airway, as well as whole 22 23 blood for paired analysis of local and systemic immune response. Nasal, bronchial, and 24 alveolar samples were analysed using a 17-plex antibody panel that captures cells of immune 25 and epithelial lineage, while tonsil, adenoid, and blood samples were analysed using a 31-26 plex antibody panel that extensively phenotypes mononuclear immune cells. All protocols, 27 panels, and data are openly available, to facilitate implementation in paediatric clinical 28 laboratories. We provide age-specific cell reference data for infancy (0-2 years), preschool (3-29 5 years), childhood (6-10 years) and adolescence (11-15 years) for 37 cell populations. We 30 show tissue-specific maturation of the airway immune system across childhood, further 31 highlighting the importance of developing age-specific references of the paediatric airway. 32 Intra-individual, cross-tissue analysis of paired samples revealed marked correlation in 33 immune cell proportions between paired nasal-bronchial samples, paired tonsil-adenoid 34 samples, and paired adenoid-blood samples, which may have implications for clinical testing. 35 Our study advances knowledge of airway immunity from infancy through to adolescence and 36 provides an openly available control dataset to aid in interpretation of clinical findings in 37 samples obtained from children with respiratory diseases.

#### 38 **INTRODUCTION**

Respiratory diseases are a major source of morbidity and hospitalisation in children worldwide. They not only cause significant short-term effects but may also have lifelong impacts on lung function <sup>1</sup>. Despite this, treatment options for children are limited, largely extrapolated from adults, and often confer little to no clinical benefit. This is due, in part, to limited understanding of the mechanisms that underly disease in children and a lack of agespecific reference ranges for cells and soluble factors present in the paediatric airway.

45 A lack of age-specific, reliable reference ranges for children extends beyond the respiratory system into all aspects of paediatric health care<sup>2, 3</sup>. Many of the available reference intervals 46 47 were determined over three decades ago using technologies that are no longer relevant in a 48 clinical setting. Despite considerable efforts to address this in recent years, current paediatric reference ranges remain largely incomplete <sup>4</sup>. The development of age-specific reference 49 50 ranges is particularly crucial in paediatric respiratory medicine due to the marked age-related 51 differences in susceptibility and immunological response to a range of infectious and chronic 52 conditions of the lung. This was recently highlighted during the COVID-19 pandemic, with children showing a markedly mild manifestation of disease compared to adults<sup>5</sup>, and is also 53 observed for other conditions including RSV infection <sup>6</sup>, wheezing, and asthma <sup>7</sup>. A better 54 understanding of immune cell composition in the healthy paediatric airway may help to 55 56 identify diagnostic biomarkers of disease, targets for anti-inflammatory therapy, and inform 57 novel interventions such as mucosal vaccination.

We aimed to develop a clinically relevant age-specific flow cytometry reference for immune cells in the upper and lower airways of children. Our secondary aims were to explore changes in immune cell composition in the first 15 years of life, understand the relationship between airway and systemic immunity, and discover cross-tissue relationships in immune cell proportions within individuals.

#### 63 <u>RESULTS</u>

# 64 65

# 1. Establishing a clinical reference for immune cells in airways and blood of children

66 To establish a reference for immune cells in the paediatric airway, we sampled five tissues 67 comprising both the upper airway (nasal brushings, palatine tonsils, adenotonsil), and lower 68 airway (bronchial brushings, BAL) from 66 children undergoing general anaesthesia at the 69 Royal Children's Hospital Melbourne. The clinical indications for these procedures are 70 provided in Supplementary Table 1, with >80% of the cohort undergoing a procedure for 71 obstructive sleep apnoea (OSA). Medical history and information on respiratory status from 72 parent questionnaires are provided in Supplementary Table 2. These children were aged 73 between 1 and 15 years, allowing for age stratification across infancy (0-2 years), preschool 74 period (3-5 years), childhood (6-10 years), and adolescence (11-15 years) (Figure 1A). 75 Furthermore, where possible, multiple airway samples were collected per participant, 76 allowing for intra-individual, cross-tissue assessment of immunity in the upper and lower 77 airway. We also analysed whole blood in order to establish a reference panel of circulating 78 immune cells and to enable associations between the systemic and respiratory immune 79 systems in childhood. Airway and blood samples were processed to single-cell suspensions 80 and analysed by spectral flow cytometry using two multiplexed panels (Figure 1B). The first 81 panel, comprising 17 markers, captures cell populations present in nasal, bronchial, and 82 alveolar samples (Supplementary Table 3). These cell types include those of both immune 83 and epithelial lineage (Figure 1C). The second panel, comprising 31 markers, captures 84 immune cell populations present in the palatine tonsil ("tonsil"), adenotonsil ("adenoid"), and 85 blood samples (Supplementary Table 4). These include all major immune cell populations 86 and their subtypes, with a focus on B- and T- cell lineages given the role of tonsils and 87 adenoids as major lymphoid niches (Figure 1D). We designed publicly available sample 88 processing and flow cytometry protocols (protocols.io/workspaces/earlyAIR) with the goal 89 they could be implemented in paediatric clinical laboratories.

90

#### 2. Immune cell landscape of paediatric nasal, bronchial, and alveolar samples

Epithelial and immune cell populations were identified in nasal, bronchial, and alveolar
samples based on expression of 16 key lineage markers (Figure 2A-C, Supplementary Figure
1). Immune cell populations identified were neutrophils, eosinophils, macrophages, NK cells,
NK-T cells, CD8 T cells, CD4 T cells, B cells, monocytes, and conventional dendritic cells

95 (cDCs). In all compartments, the immune cell lineage outnumbered the epithelial lineage, 96 particularly more distally through the airway (Figure 2D-F). In nasal samples, immune cells 97 comprised a median of 74.3% of all cells, bronchial samples 88%, and alveolar samples 98% 98 (Figure 2D-F). Median proportions of the 10 major immune cell subtypes in each sample type 99 are shown in Figure 2G-I. To help develop age-specific references for each of these tissues, 100 the median and range of each cell population are reported by clinically relevant age groups 101 (all ages (age 1-15 years), infancy (0-2 years), preschool (3-5 years), childhood (6-10 years), 102 adolescence (11-15 years)) and presented in Tables 1-3. For nasal samples, all five age 103 analyses are reported (Table 1). For bronchial and alveolar samples, due to more limited 104 numbers, a subset of these age groups is reported (Tables 2-3).

#### 105

## 3. Immune cell landscape of paediatric tonsil, adenoid, and blood samples.

106 Immune cell populations were identified in tonsil, adenoid and whole blood samples based on 107 expression of 22 lineage markers (Figure 3A-C, Supplementary Figure 2). In tonsils and 108 adenoids, 25 immune cell populations were quantified, and in whole blood 30 immune cell 109 populations were quantified. Additional populations observed in blood that were not observed in tonsil/adenoid tissue include eosinophils, CD56<sup>bright</sup> subsets of NK cells and subsets of 110 111 CD16 expressing monocytes including non-classical and intermediate monocytes. On the 112 other hand, germinal centre (GC) B cells, one of the most abundant populations in tonsils and 113 adenoids, were not observed in blood. Mean Fluorescence Intensity (MFI) analysis of marker 114 expression revealed differential surface receptor patterns across the three compartments 115 including: CD24 expression on NK and NK-T cells from adenoid and tonsil tissue that is not 116 observed on the respective blood populations; high expression of CD38 on T cell populations 117 in tissue: and CXCR5 expression NK-T cells in tissue (Figure 3A-C). Median proportions of 118 immune cell populations in all tonsil, adenoid, and blood samples are shown in Figure 3D-F, 119 respectively. To help develop age-specific references for each of these tissues, the median and 120 range of each cell population are reported by clinically relevant age groups (all ages, infancy, 121 preschool, childhood, adolescence) and presented in Tables 4-6.

122

## 4. Airway and blood immune cell dynamics over the first 15 years of life

To identify age-specific cellular associations, we performed two-tailed spearman correlation analyses on cell proportion data in each tissue from children aged 1-15 years. No significant age associations for immune cell populations were seen in nasal or alveolar samples after correction for the false discovery rate. In contrast, for bronchial samples, macrophages and

127 NK-T cells increased with age (spearman coefficient ( $\rho$ )=0.80, FDR-P=0.002;  $\rho$ =0.63, FDR-128 P=0.03, respectively) while a subset of neutrophils expressing intermediate levels of 129 activation marker CD66b and high levels of CD16 reduced with age ( $\rho$ = -0.71, FDR-P=0.01) 130 (Figure 4A). In tonsil samples, transitional B cells decreased with age ( $\rho$ = -0.62, FDR-131 P=0.002), while classical memory B cells, CD8 TEM cells and CD4 Thelper cells increased 132 with age ( $\rho$ =0.51, FDR-P=0.02;  $\rho$ =0.47, FDR-P=0.04;  $\rho$ =0.63, FDR-P=0.002, respectively) 133 (Figure 4B). The same associations with age were also observed in adenoid samples, where 134 transitional B cells decreased with age ( $\rho$ = -0.51, FDR-P=0.007) and classical memory B 135 cells, CD8 TEM and CD4 Thelper cells increased with age ( $\rho$ =0.43, FDR-P=0.02;  $\rho$ =0.52, 136 FDR-P=0.006;  $\rho$ =0.62, FDR-P=0.0008, respectively) (Figure 4C). Additionally, four other 137 adenoid immune cells were also associated with age. These were GC B cells and T follicular 138 helper (TFH) cells which decreased with age ( $\rho = -0.41$ , FDR-P=0.03;  $\rho = -0.42$ , FDR-P=0.02, 139 respectively), and non-switched memory B cells and NK-T cells which increased with age 140  $(\rho=0.69, FDR-P=0.0008; \rho=0.62, FDR-P=0.0008, respectively)$  (Figure 4C). Like the tonsil 141 and adenoid tissue, blood transitional B cells, NK-T cells, and CD4 Thelper cells were also 142 associated with age ( $\rho$ = -0.52, FDR-P=0.001;  $\rho$ =0.47, FDR-P=0.005;  $\rho$ =0.44, FDR-P=0.009, 143 respectively) (Figure 4D). Blood neutrophils increased with age ( $\rho = 0.40$ , FDR-P=0.02), 144 while intermediate monocytes and cDCs decreased with age ( $\rho$ = -0.42, FDR-P=0.01;  $\rho$ = -145 0.38, FDR-P=0.02) (Figure 4D). Blood CD4 TN cells decreased with age ( $\rho$ =-0.34, FDR-146 P=0.049) and CD8 TEM cells also tended to increase with age ( $\rho$ =0.31, raw-P=0.04, FDR-147 P=0.09). Individual dot plots depicting correlations for each significant cell type in each 148 tissue are presented in Supplementary Figures 3 and 4.

149 These results demonstrate maturation of the airway immune system with age, centred around 150 the development of memory B cells, memory CD8 T cells, and CD4 Teffector populations. 151 Notably, NK-T cell proportions were also highly dynamic, increasing significantly with age 152 in three locations (bronchial, adenoid, and blood) as well as in the alveolar region albeit not 153 significantly when correcting for FDR ( $\rho$ =0.88, raw-P=0.007, FDR-P=0.1).

154

## 5. Cross-tissue analysis of cell type proportions in the upper and lower airway

We next directly compared the composition of immune cells across nasal, bronchi, and alveolar regions. As can be seen in Figure 5A, cell type proportions vary throughout the airway, with granulocytes (neutrophils and eosinophils) more highly abundant in nasal and bronchial tissues; a progressive increase in the proportions of macrophages down the airway;

159 and a shift from CD8 T cell dominance in nasal samples to more equal CD8:CD4 T cell ratios 160 in the alveolar region. Cross-sectional statistical analysis showed that proportions of 161 granulocytes were significantly higher in both the nasal and bronchial samples when 162 compared to alveolar samples (Figure 5B). Macrophage proportions were significantly higher 163 in bronchial compared to nasal, in alveolar compared to nasal, and in alveolar compared to 164 bronchial samples (Figure 5B). Regarding lymphocytes, CD8 T cells and B cells were 165 significantly higher in the nasal than the alveolar samples, and NK-T cells were significantly 166 lower in nasal samples when compared to bronchial samples (Figure 5B). The list of 167 significant cell types and their associated medians and FDR-P values are reported in 168 Supplementary Table 5.

169 As we had collected multiple sample types per participant, we were able to test for 170 correlations in immune cell proportions between the upper and lower airway in the same 171 individuals. Due to limited numbers of paired BAL-nasal, and paired BAL-bronchial 172 samples, we could not perform this analysis for these sample types. However, we were able 173 to perform cross-tissue analysis for paired nasal and bronchial samples (n=13), paired nasal 174 and blood samples (n=29) and paired bronchial and blood samples (n=15). This revealed that 175 nasal and bronchial samples were highly correlated within individuals, with positive 176 correlations observed between eosinophils (spearman coefficient ( $\rho$ )=0.85, FDR-P=0.002), 177 neutrophils ( $\rho=0.64$ , FDR-P=0.03), CD4 T cells ( $\rho=0.70$ , FDR-P=0.02), CD8 T cells ( $\rho=0.69$ , 178 FDR-P=0.02), monocytes ( $\rho$ =0.72, FDR-P=0.02) and cDCs ( $\rho$ =0.92, FDR-P=0.0002) in the 179 nasal and bronchial samples (Figure 5C). On the contrary, we observed no statistical 180 correlation in immune cell proportions between blood and nasal samples within individuals, 181 and only NK-T cells were significantly correlated between blood and bronchial samples 182  $(\rho=0.72, FDR-P=0.03)$  (Figure 5C). All correlation coefficients and FDR-P values are 183 reported in Supplementary Table 6.

184

# 6. Cross-tissue analysis of cell type proportions in the upper airway lymphoid tissue

Next, we directly compared the composition of immune cells across tonsil, adenoid, and blood compartments. As can be seen in Figure 6A, tonsil and adenoid cell compositions were similar, particularly for NK-T cells, innate lymphoid cells (ILCs), all CD8 T cell subsets, all CD4 T cell subsets and Tregulatory cells. Blood samples showed higher frequencies of innate immune cells, NK/ILCs, as well as naïve CD8- and CD4- T cells, and lower frequencies of TFH cells and the B cell lineage when compared to tonsils and adenoids (Figure 6A,

191 statistical comparison presented in Supplementary Figure 5). Cross-sectional statistical 192 comparison of tonsils vs adenoids showed that plasmablasts, GC B cells, and neutrophils 193 were significantly higher in tonsils compared to adenoids, while pDCs, NK cells, classical 194 memory B cells, and non-switched memory B cells were significantly higher in adenoids 195 compared to tonsils (Figure 6B). The list of significant cell types and their associated 196 medians and FDR-P values are reported in Supplementary Table 7.

197 Finally, we tested for correlations in immune cell proportions between tonsil, adenoid, and 198 blood compartments in paired samples collected from the same individuals (Figure 6C). 199 There were 27 children with paired tonsil and adenoid samples, 25 children with paired tonsil 200 and blood samples, and 30 children with paired adenoid and blood samples. This cross-tissue 201 analysis revealed that tonsil and adenoid samples were highly correlated within individuals, 202 with positive associations observed between 19/25 immune cell populations identified in the 203 lymphoid tissues (Figure 6C). Similarly, blood cells also correlated with cells in the upper 204 airway lymphoid tissue, especially evident for the adenoids where 7/24 populations were 205 positively correlated (Figure 6C). Blood cell proportions positively correlated with tonsil cell 206 proportions for atypical memory B cells, transitional B cells, and CD8 TN within individuals. 207 Blood cell proportions positively correlated with adenoid cell proportions for atypical 208 memory B cells, classical memory B cells, plasma cells, CD8 TCM, CD8 TEM, naïve Tregs 209 and pDCs within individuals. All correlation coefficients and associated FDR-P values are 210 reported in Supplementary Table 8.

## 211 DISCUSSION

In recent years, there has been an explosion in the development of single-cell sequencing 212 213 based tissue atlases, including a global consortium dedicated to profiling the lung<sup>8</sup>. These 214 studies have provided an unprecedented level of resolution into gene expression of individual 215 cells across many populations. However, due to the extensive laboratory and specialist 216 computational pipelines required for analysis of single-cell sequencing data, these tools are 217 many years away from application in clinical laboratories. Flow cytometry is routinely used 218 in the diagnosis and assessment of human disease globally, and permits multi-dimensional, 219 high-throughput quantification of millions of cells without the requirement for specialist computational analysis<sup>9</sup>. To our knowledge, we have developed the first flow cytometry-220 221 based reference for immune cells in the airways of children. This includes detailed 222 assessment of cell populations in the nose, upper airway lymphoid tissue, as well as the lower 223 airway epithelium and alveolar space; a detailed analysis of surface markers present on each 224 cell population in each tissue; and investigation of cell frequencies across time and space. We 225 also present a reference for immune cells in whole blood samples collected from the same 226 children. The goal of this work was to understand the relationship between airway and 227 systemic immunity from paired paediatric samples, however we also hope it adds valuable 228 data to other efforts investigating immune development in blood, including fresh whole blood <sup>10</sup>, cryopreserved whole blood <sup>11</sup>, and cryopreserved PBMC <sup>12</sup> samples. To facilitate the 229 230 application and implementation of our tissue references, all protocols, flow cytometry panels, 231 and data are openly available.

232 Our results show tissue-specific maturation of the airway immune system with age. For 233 example, we did not show changes in immune cell proportions throughout childhood in nasal 234 samples, however a marked increase in macrophages and NK-T cells were observed during 235 childhood in bronchial samples. We were fascinated to find strikingly high immune:epithelial 236 cell ratios in nasal and bronchial brushings samples, particularly the high proportions of 237 neutrophils. A recent study that used single-cell sequencing to profile immune cells in nasal 238 swabs from children with SARS-CoV-2 infection as well as non-infected controls reported 239 similar findings. They showed that while immune cells were rarely detected in nasal swabs 240 from healthy adults, samples from healthy children contained high amounts of immune cell subsets with an overall dominance of neutrophils<sup>13</sup>. Regarding the lymphoid tissues, both 241 242 tonsil and adenoid samples showed increases in classical memory B cells, CD8 TEM cells 243 and CD4 Thelper cells with age, as well as a decrease in transitional B cells. Adenoid cells,

244 however, appeared more influenced by age, with additional significant associations observed 245 in germinal centre B cells, non-switched memory B cells, NK-T cells and TFH cells. Similar 246 age-related changes in airway lymphoid tissues have been observed previously, particularly related to germinal centre development in tonsils<sup>14</sup>. For blood immune cells, we replicate 247 248 what has been observed in another study focusing on lymphocyte populations from a large 249 number of paediatric whole blood samples where plasmablasts, transitional B cells, and CD4 250 T naïve cells decreased with age and CD4 Thelper cells increased with age <sup>10</sup>. We 251 additionally show that whole blood NK-T cells, neutrophils, cDCs, and intermediate 252 monocytes are also associated with age. Collectively, these age-related changes in immune 253 cell composition further highlight the importance of developing age-specific references for 254 the airways and blood of children. This work also highlights that many single-cell sequencing 255 based tissue atlases that primarily consist of samples obtained from adults may not be 256 applicable to children, and we support the efforts of the Pediatric Cell Atlas to include data that samples the complete human lifespan<sup>15</sup>. 257

258 Our intra-individual cross-tissue analysis revealed high correlation in immune cell 259 proportions between tissues, particularly for paired nasal and bronchial samples, paired tonsil 260 and adenoid samples, and paired adenoid and blood samples. These findings suggest that 261 easily accessible nasal samples could be used as a surrogate for assessment of immunity in 262 the lower airway of children. If validated in future studies, this could have important 263 implications for clinical testing, and potentially prevent risks associated with general 264 anaesthesia to sample the lower airway. The remarkable correlation in immune cell 265 composition between the tonsils and adenoids is likely explained by the fact both tissues are 266 part of Waldeyer's ring of pharyngeal lymphoid organs.

267 We acknowledge the limitations of our dataset, in particular the limited number of BAL 268 samples which did not permit age-related or cross-tissue analysis for this sample type. This is 269 due to the difficulties in obtaining these lower airway samples from children, as well as 270 limitations in sample volumes for research testing. However, we were able to obtain samples 271 from a larger number of children for all other sample types (n=17-49), and these numbers are 272 similar to or above that of other immunological studies using paediatric respiratory specimens <sup>13, 16-18</sup>. We also acknowledge that these samples were collected as part of clinically indicated 273 274 procedures, which means that not all samples can be considered 'healthy'. The main 275 indication in our cohort was OSA, with >80% of samples obtained from children exhibiting 276 or undergoing investigation for this indication. While this may contribute to some variation in

tonsil or adenoid immune cell proportions<sup>18</sup>, the effect of this underlying condition on results 277 278 obtained from distal sample types in these children (nasal brushings, bronchial brushings, 279 blood) is unclear. A recent review revealed conflicting evidence of immune cell alterations in 280 adult and paediatric OSA, with some studies reporting an inflammatory effect while others reported normal immune responses in these patients <sup>19</sup>. All children in our cohort were 281 282 clinically well at the time of sample collection and there was limited evidence of wheezing or 283 respiratory infection in the week leading up to sample collection. Parent questionnaires 284 revealed that the majority of children in our cohort had never been prescribed respiratory 285 medications, and of those prescribed, rates of medication use were similar to what is observed in the Australian community for children aged 0-15 years<sup>20</sup>. Likewise, rates of conditions 286 including general atopy, asthma, and eczema, were similar to a recent population-based study 287 of Australian children<sup>21</sup>. As general anaesthesia is required to collect many of the sample 288 289 types included in our study, creating control respiratory datasets from healthy children in the 290 community is not feasible, especially datasets that include multiple sample types from the 291 same individual, Our reference can be used as control data for clinical samples collected from 292 children with acute (e.g. infectious), rare (e.g. cystic fibrosis, primary ciliary dyskinesia) and 293 chronic (e.g. suppurative lung disease) respiratory conditions.

In summary, this study advances our knowledge of airway immunity from infancy through to adolescence and provides an easily adaptable, publicly available control dataset to aid in interpretation of clinical samples obtained from children with respiratory disease.

## 297 MATERIALS AND METHODS

298

#### 299 Study participants

This study took place at the Royal Children's Hospital (RCH, Melbourne Australia) and involved analysis of 178 samples from 66 children (Figure 1A, Supplementary Table 1) aged between 1 and 15 years. Samples were collected at the time of clinically indicated procedures (bronchoscopy, tonsillectomy and/or adenoidectomy). Reasons for procedures are detailed in Supplementary Table 1 and medical history from parent questionnaires are summarised in Supplementary Table 2.

## **306** Collection and processing of samples

307 Samples were collected at the time of clinically indicated procedures (bronchoscopy, 308 tonsillectomy and/or adenoidectomy). For palatine tonsils ("tonsils") and adenotonsils 309 ("adenoids"), tissues were removed by the operating team as per standard operating 310 procedures, suspended in RPMI media supplemented with 2% fetal calf serum (FCS), and 311 transferred on ice to the laboratory immediately upon collection. For nasal brushings, samples 312 were collected by a respiratory physician using a 3mm cytology brush at the time of the 313 procedure, suspended in cold RPMI media supplemented with 2% FCS and transferred on ice 314 to the laboratory immediately upon collection. Bronchial brushings were collected by a 315 respiratory physician using a 2mm cytology brush and suspended in cold RPMI media 316 supplemented with 2% FCS and transferred on ice to the laboratory immediately upon 317 collection. Bronchoscopy and bronchoalveolar lavage (BAL) were performed as previously described where indicated for investigation of stridor <sup>22</sup>. This study used BAL from aliquots 318 319 two and three from the right middle lobe. BAL samples were transferred on ice to the 320 laboratory immediately upon collection. Venous blood was collected in EDTA tubes at the 321 time of the procedure and transferred to the laboratory at room temperature immediately upon 322 collection. Multiple sample types were collected from each individual (Figure 1A).

Detailed protocols for the collection, processing and flow cytometry analysis of each sample type are openly available at: protocols.io/workspaces/earlyAIR. Briefly, cells were dislodged off nasal and bronchial brushes into media by pipetting for at least 1 minute. Cells were filtered through a 70μM cell strainer into a new 15mL tube and centrifuged at 300xg for 7 minutes at 4 degrees. Cells were counted using the LUNA-FL Dual Fluorescence cell counter and washed once more before 300,000 cells were aliquoted for flow cytometry as described

329 below. BAL samples were centrifuged at 300xg for 7 minutes at 4 degrees. The cell-free 330 supernatant was removed and cells were resuspended in 10mL of media. Cells were filtered 331 through a  $70\mu$ M cell strainer into a new 15mL tube and centrifuged at 300xg for 7 minutes at 332 4 degrees. Cells were counted using the LUNA-FL cell counter and washed once more before 333 300,000 cells were aliquoted for flow cytometry as described below. Tonsil and adenoid 334 samples were processed in glass culture plates with 10mL of media. First, visible blood clots, 335 fat and connective tissue were removed using forceps and scissors. Next, the tissues were 336 minced into a fine paste using scissors in a fresh glass plate with fresh media and filtered 337 through a 100µm cell strainer into a 50mL tube. Cells were centrifuged at 400xg for 5 338 minutes at room temperature and resuspended in 8mL of fresh media prior to layering onto 339 Ficoll plaque plus as per the manufacturer's instructions. Cells were centrifuged at 400xg for 340 30 minutes at room temperature with a slow acceleration and no brake. Cells at the interface 341 between media and the Ficoll solution were collected into a new 15mL tube and washed with 342 media before counting using the LUNA-FL cell counter. Due to the large number of cells 343 collected, cells were diluted between 1:10-1:100 prior to counting. Finally, 500,000 cells 344 were aliquoted for flow cytometry as described below.

#### 345 Flow cytometry of nasal brushings, bronchial brushings, and BAL samples

346 Nasal, bronchial and BAL cells were resuspended in PBS for viability staining using near 347 infra-red viability dye according to manufacturers' instructions. The viability dye reaction 348 was stopped by the addition of FACS buffer (2% heat-inactivated FCS in PBS) and cells were 349 centrifuged at 400xg for 5 mins 4°C. Cells were resuspended in 25µL human FC-block 350 (diluted 1:10) for 5 minutes at room temperature. The flow cytometry staining panel 351 described in Supplementary Table 3 (made up at 2X concentration) was added 1:1 with the 352 cells and incubated for 30 minutes on ice. Following staining, cells were washed with 1mL 353 FACS buffer and centrifuged at 400xg for 5 minutes 4°C. Cells were resuspended in 150µL 354 FACS buffer for acquisition using the Cytek 5L Aurora. The gating strategy used to define 355 cell types obtained with this panel is depicted in Supplementary Figure 1.

## 356 Flow cytometry of tonsils, adenoids, and whole blood samples

Tonsil, adenoid and lysed whole blood cells were resuspended in PBS for viability staining using near UV-blue viability dye according to manufacturers' instructions. The viability dye reaction was stopped by the addition of FACS buffer and cells were centrifuged at 400xg for 5 mins 4°C. Cells were resuspended in 40μL human FC-block (diluted 1:10) for 5 minutes at

361 room temperature, following which 10µL of Brilliant Stain Buffer Plus was added. The 362 chemokine panel described in Supplementary Table 4A (made up at 3X concentration) was 363 added at  $25\mu$ L per sample and cells incubated for 10 minutes at room temperature in the dark. 364 The panel described in Supplementary Table 4B (made up at 3X concentration) was added at 365 50µL per sample and cells incubated for 30 minutes at room temperature in the dark. 366 Following staining, cells were washed with 1mL FACS buffer and centrifuged at 400xg for 5 367 minutes 4°C. Cells were resuspended in 150µL FACS buffer for acquisition using the Cytek 368 5L Aurora. The gating strategy used to define cell types obtained with this panel is depicted 369 in Supplementary Figure 2. The panel described in Supplementary Table 4 is a modified version of the published OMIP-069<sup>23</sup>. 370

#### 371 Data analysis

372 Gating of flow cytometry data was performed in FlowJo version 10.9.0. As samples were 373 acquired fresh on the day of collection over multiple batches, all data was normalised using the cyCombine plugin<sup>24</sup>. For each tissue type, cell populations were annotated based on 374 375 expression of known lineage markers included in each panel (see gating strategies for each 376 tissue in the Supplement). Cell population frequencies were expressed as a proportion of live, 377 single cells or as a proportion of live, single, CD45<sup>+</sup> cells when referring to analysis of 378 immune cell types only. For age-specific immune cell reference ranges (Tables 1-6), median 379 frequencies (% of live, single,  $CD45^+$  cells) were calculated for each cell type within each 380 age group (0-2years, 3-5 years, 6-10 years, 11-15 years) and the ranges also reported. For 381 unsupervised analyses, a single concatenated file was created for each tissue type, containing 382 10,000 downsampled cells from each participant. These concatenated files were used for 383 Uniform Manifold Approximation and Projection (UMAP) analysis (using the default settings 384 of the UMAP plugin for FlowJo) and to calculate the median fluorescence intensity (MFI) of 385 each lineage marker for each cell type in each tissue. Hierarchical clustering analysis and 386 heatmap visualisation of the MFI data was done using the pheatmap package in R Studio 387 version 4.3.0. For cross-sectional statistical analysis, cell proportions were compared using 388 Mann Whitney U-tests. All p-values were corrected for false discovery rate using the Benjamini and Hochberg approach  $^{25}$ . An FDR corrected p<0.05 and a fold change of >1.5 389 390 was required to reach statistical significance. Age and intra-individual correlations were 391 determined using two-tailed spearman tests. Spearman P-values were corrected for false 392 discovery rate using the Benjamini and Hochberg approach. An FDR corrected p<0.05 was 393 required to reach statistical significance.

# **394** Ethics statement

- 395 The studies involving human participants were reviewed and approved by Royal Children's
- 396 Hospital Human Research Ethics Committee (HREC #25054 and # 88144). Written informed
- 397 consent to participate in the studies was provided by the participants' legal guardian/next of
- 398 kin.

#### 399 **References**

- Stocks, J., Hislop, A. & Sonnappa, S. Early lung development: lifelong effect on respiratory health and disease. *Lancet Respir Med* 1, 728-742 (2013).
- 402 2. Schnabl, K., Chan, M.K., Gong, Y. & Adeli, K. Closing the gaps in paediatric
  403 reference intervals: the CALIPER initiative. *Clin Biochem Rev* 29, 89-96 (2008).
- 404 3. Tosato, F. *et al.* Lymphocytes subsets reference values in childhood. *Cytometry. Part*405 *A : the journal of the International Society for Analytical Cytology* 87, 81-85 (2015).
- 406 4. Lyle, A.N. *et al.* Current State of Pediatric Reference Intervals and the Importance of
  407 Correctly Describing the Biochemistry of Child Development: A Review. *Jama*408 *Pediatr* 176, 699-714 (2022).
- 409 5. Zimmermann, P. & Curtis, N. Why is COVID-19 less severe in children? A review of
  410 the proposed mechanisms underlying the age-related difference in severity of SARS411 CoV-2 infections. archdischild-2020-320338 (2020).
- 412 6. Coultas, J.A., Smyth, R. & Openshaw, P.J. Respiratory syncytial virus (RSV): a scourge from infancy to old age. *Thorax* 74, 986-993 (2019).
- 414 7. Morris, I. *et al.* Which intravenous bronchodilators are being administered to children
  415 presenting with acute severe wheeze in the UK and Ireland? *Thorax* 70, 88-91 (2015).
- 8. Sikkema, L. *et al.* An integrated cell atlas of the lung in health and disease. *Nature Medicine* 29, 1563-1577 (2023).
- 418 9. Virgo, P.F. & Gibbs, G.J. Flow cytometry in clinical pathology. *Annals of Clinical Biochemistry* 49, 17-28 (2012).
- 420 10. Ding, Y. *et al.* Reference values for peripheral blood lymphocyte subsets of healthy
  421 children in China. *J Allergy Clin Immunol* 142, 970-973.e978 (2018).
- 422 11. Olin, A. *et al.* Stereotypic Immune System Development in Newborn Children. *Cell*423 174, 1277-1292.e1214 (2018).
- Jalali, S. *et al.* A high-dimensional cytometry atlas of peripheral blood over the human
  life span. *Immunol Cell Biol* 100, 805-821 (2022).
- 426 13. Loske, J. *et al.* Pre-activated antiviral innate immunity in the upper airways controls
  427 early SARS-CoV-2 infection in children. *Nat Biotechnol* 40, 319-324 (2022).
- 428 14. Massoni-Badosa, R. *et al.* An atlas of cells in the human tonsil. *Immunity* 57, 379429 399.e318 (2024).
- 430 15. Taylor, D.M. *et al.* The Pediatric Cell Atlas: Defining the Growth Phase of Human
  431 Development at Single-Cell Resolution. *Developmental Cell* 49, 10-29 (2019).
- 432 16. King, H.W. *et al.* Single-cell analysis of human B cell maturation predicts how antibody class switching shapes selection dynamics. *Science immunology* 6 (2021).
- 434 17. Neeland, M.R. *et al.* Pulmonary immune profiling reveals common inflammatory
  435 endotypes of childhood wheeze and suppurative lung disease. *Mucosal Immunol*436 (2024).
- 437 18. Carrasco, A. *et al.* The Tonsil Lymphocyte Landscape in Pediatric Tonsil Hyperplasia
  438 and Obstructive Sleep Apnea. *Frontiers in immunology* 12, 674080 (2021).
- 439 19. Ludwig, K., Huppertz, T., Radsak, M. & Gouveris, H. Cellular Immune Dysfunction in Obstructive Sleep Apnea. *Front Surg* 9, 890377 (2022).
- 441 20. Welfare, A.I.o.H.a. Asthma. (2023).
- Peters, R.L. *et al.* The Prevalence of IgE-Mediated Food Allergy and Other Allergic
  Diseases in the First 10 Years: The Population-Based, Longitudinal HealthNuts Study. *The journal of allergy and clinical immunology. In practice* (2024).
- 445 22. Sly, P.D. *et al.* Risk factors for bronchiectasis in children with cystic fibrosis. *N Engl J*446 *Med* 368, 1963-1970 (2013).

- Park, L.M., Lannigan, J. & Jaimes, M.C. OMIP-069: Forty-Color Full Spectrum Flow
  Cytometry Panel for Deep Immunophenotyping of Major Cell Subsets in Human
  Peripheral Blood. *Cytometry A* 97, 1044-1051 (2020).
- 450 24. Pedersen, C.B. *et al.* cyCombine allows for robust integration of single-cell cytometry
  451 datasets within and across technologies. *Nat Commun* 13, 1698 (2022).
- 452 25. Benjamini, Y. & Hochberg, Y. Controlling the False Discovery Rate a Practical and
  453 Powerful Approach to Multiple Testing. *J R Stat Soc B* 57, 289-300 (1995).
- 454
- 455

# 456 ACKNOWLEDGEMENTS

- 457 This work was funded by a Chan Zuckerberg Initiative Single-Cell Biology Grant (2021-
- 458 237883). We thank the children and parents who participated in our studies, without whom459 this work would not exist.
- 460

461

## 462 **FIGURE LEGENDS**

463 Figure 1. Overview of the experimental design and cellular landscape of each tissue. (A) 66 464 children aged between 1 and 15 years were recruited into the earlyAIR study. There were 10 465 infants (age 0-2 years), 21 preschoolers (age 3-5 years), 22 children (6-10 years), and 13 466 adolescents (11-15 years). From these 66 children, 178 samples were collected across six 467 tissue types: nasal brushings (n=37), bronchial brushings (n=17), bronchoalveolar lavage 468 (BAL) (n=8), adenoids (n=36), tonsils (n=31), and whole blood (n=49). (B) Each sample type 469 was processed into a single-cell suspension and analysed by spectral flow cytometry. Nasal 470 brushing, bronchial brushing, and BAL samples were analysed using a 17-plex lung panel. 471 Tonsil, adenoid, and whole blood samples were analysed using a 31-plex tonsil-adenoid-472 blood panel. (C) Uniform Manifold Approximation and Projection (UMAP) plots showing 473 the cellular landscape of nasal, bronchial and alveolar cells identified using the lung panel. 474 (D) UMAP plots showing the cellular landscape of tonsil, adenoid, and blood cells identified 475 using the tonsil-adenoid-blood panel.

476 **Figure 2.** Marker expression and proportion of cell populations identified in paediatric nasal, 477 bronchial, and alveolar samples. (A) Heatmap depicting hierarchical clustering analysis of the 478 normalised median fluorescence intensity (MFI) of 16 lineage markers on cell types 479 identified in nasal brushings samples. (B) Heatmap depicting hierarchical clustering analysis 480 of the normalised MFI of 16 lineage markers on cell types identified in bronchial brushings 481 samples. (C) Heatmap depicting hierarchical clustering analysis of the normalised MFI of 16 482 lineage markers on cell types identified in BAL samples. (D) Proportion of immune and 483 epithelial linages in nasal brushings samples. (E) Proportion of immune and epithelial linages 484 in bronchial brushings samples. (F) Proportion of immune and epithelial linages in BAL 485 samples. (G) Box plots depicting individual cell proportions for 10 broad immune cell types 486 identified in nasal brushings samples (H) Box plots depicting individual cell proportions for 487 10 broad immune cell types identified in bronchial brushings samples. (I) Box plots depicting 488 individual cell proportions for 10 broad immune cell types identified in BAL samples. P-489 values determined by Mann-Whitney U-test where p<0.05 was considered significant.

490 Figure 3. Marker expression and proportion of cell populations identified in paediatric tonsil, 491 adenoid, and whole blood samples. (A) Heatmap depicting hierarchical clustering analysis of 492 the normalised median fluorescence intensity (MFI) of 22 lineage markers on cell types 493 identified in tonsils. (B) Heatmap depicting hierarchical clustering analysis of the normalised 494 MFI of 22 lineage markers on cell types identified in adenoids. (C) Heatmap depicting 495 hierarchical clustering analysis of the normalised MFI of 22 lineage markers on cell types 496 identified in blood. (D) Box plots depicting individual cell proportions for 25 immune cell 497 types identified in tonsils. (E) Box plots depicting individual cell proportions for 25 immune 498 cell types identified in adenoids. (F) Box plots depicting individual cell proportions for 30 499 immune cell types identified in whole blood samples.

500 Figure 4. Immune cell type proportions in bronchial, tonsil, adenoid and blood samples are 501 associated with age. (A) Spearman coefficient (p) and FDR-corrected p-values for nasal immune cell types significantly associated with age: CD66b<sup>low</sup>CD16<sup>+</sup> neutrophils, 502 503 macrophages, and NK-T cells. (B) Spearman  $\rho$  and FDR-corrected p-values for bronchial 504 immune cell types significantly associated with age: transitional B cells, classical memory B 505 cells, CD8  $T_{EM}$ , and CD4 Thelper cells. (C) Spearman  $\rho$  and FDR-corrected p-values for 506 adenoid immune cell types significantly associated with age: germinal centre B cells, 507 transitional B cells, non-switched memory B cells, classical memory B cells, CD4 Thelper 508 cells, NK-T cells, CD8  $T_{EM}$ , and TFH cells. (D) Spearman  $\rho$  and FDR-corrected p-values for 509 blood immune cell types significantly associated with age: plasmablasts, transitional B cells,

510 NK-T cells, CD4 TN cells, CD4 Thelper cells, neutrophils, intermediate monocytes, and 511 cDCs. Note there were no significant correlations with age for cell types in nasal or alveolar 512 samples. Correlation p-values were determined by two-tailed spearman test and corrected for 513 false discovery rate using the Benjamini Hochberg approach. FDR-P<0.05 was considered 514 significant.

515 Figure 5. Cross-tissue analysis of cell type proportion in lung and blood compartments 516 reveals high correlation between upper and lower airway brushings but limited correlation 517 between the lung and blood in children. (A) Median immune cell type proportion in nasal, 518 bronchial, and alveolar samples for granulocytes (left panel), myeloid cells (centre panel) and 519 lymphocytes (right panel). (B) Volcano plots depicting cross-sectional statistical analysis of 520 cell types in nasal\_vs\_bronchial samples (left panel), nasal\_vs\_alveolar samples (centre 521 panel), and bronchial\_vs\_alveolar samples (right panel). (C) Ballon plot depicting intra-522 individual correlations of cell type proportions for participants who had nasal, bronchial, and 523 blood samples analysed. \* Depicts significant correlation. NA: Not Applicable, as 524 macrophages are not present in blood. Cross-sectional p-values (part B) were determined by 525 Mann-Whitney U-test and corrected for false discovery rate using the Benjamini Hochberg 526 approach. FDR p<0.05 and fold change >1.5 was considered significant. Intra-individual 527 correlation p-values (part C) were determined by two-tailed spearman test and corrected for 528 false discovery rate using the Benjamini Hochberg approach. FDR-P<0.05 was considered 529 significant.

530 Figure 6. Cross-tissue analysis of cell type proportion in tonsil, adenoid and blood 531 compartments reveals sample-type specific immune cell profiles and an intra-individual 532 tonsil-adenoid-blood immune cell axis in children. (A) Median immune cell type proportion 533 in tonsil, adenoid, and blood samples for granulocytes and myeloid cells (first panel), innate 534 lymphocytes (second panel), CD8 T cell populations (third panel), CD4 T cell populations 535 (fourth panel) and B cell populations (fifth panel). (B) Volcano plot depicting cross-sectional 536 statistical analysis of cell types in tonsil\_vs\_adenoid samples. (C) Ballon plot depicting intra-537 individual correlations of cell type proportions for participants who had tonsil, adenoid, and 538 blood samples analysed. \* Depicts significant correlation. NA: Not Applicable, as GC B cells 539 are not present in blood. Cross-sectional p-values (part B) were determined by Mann-540 Whitney U-test and corrected for false discovery rate using the Benjamini Hochberg 541 approach. FDR p<0.05 and fold change >1.5 was considered significant. Intra-individual 542 correlation p-values (part C) were determined by two-tailed spearman test and corrected for 543 false discovery rate using the Benjamini Hochberg approach. FDR-P<0.05 was considered 544 significant.

545	Table 1. Immune cell subtype frequency in nasal brushings samples from children aged 0-15
546	years.

NASAL IMMUNE CELLS	0-15 years (n=37)	<b>0-2 years</b> (n=5)	<b>3-5 years</b> (n=16)	<b>6-10 years</b> (n=12)	<b>11-15 years</b> (n=4)
<b>Total granulocytes</b> % CD45 <sup>+</sup> cells Median (range)	31.72 (2.92-88.20)	29.09 (23.42-79.66)	46.03 (6.93-79.63)	20.40 (2.92-88.20)	51.67 (42.28-64.37)
<b>Eosinophils</b> %CD45 <sup>+</sup> cells Median (range)	0.22 (0.01-31.62)	0.34 (0.16-0.50)	0.16 (0.02-2.16)	0.61 (0.01-31.62)	0.63 (0.02-21.92)
<b>Neutrophils</b> % CD45 <sup>+</sup> cells Median (range)	28.17 (2.51-78.26)	28.17 (20.55-71.76)	42.84 (6.83-78.26)	14.35 (2.51-60.89)	43.52 (39.82-52.74)
Macrophages %CD45 <sup>+</sup> cells Median (range)	0.99 (0.27-13.63)	1.16 (0.30-8.37)	0.78 (0.27-9.69)	1.14 (0.46-13.63)	1.16 (0.79-3.29)
NK cells % CD45 <sup>+</sup> cells Median (range)	0.64 (0.12-3.96)	1.03 (0.48-2.9)	0.74 (0.12-3.96)	0.42 (0.15-3.39)	0.59 (0.31-0.60)
NK-T cells % CD45 <sup>+</sup> cells Median (range)	0.16 (0.01-2.23)	0.27 (0.06-2.23)	0.10 (0.04-1.02)	0.13 (0.01-0.62)	0.18 (0.02-0.23)
<b>CD8 T cells</b> % CD45 <sup>+</sup> cells Median (range)	20.71 (1.36-43.14)	20.25 (6.48-31.47)	19.09 (1.36-43.14)	22.12 (1.71-31.69)	24.29 (13.34-35.89)
<b>CD4 T cells</b> % CD45 <sup>+</sup> cells Median (range)	5.91 (0.23-17.72)	8.94 (0.23-17.72)	5.19 (1.54-14.64)	9.33 (1.91-16.90)	4.32 (3.46-7.00)
<b>B cells</b> %CD45 <sup>+</sup> cells Median (range)	3.92 (0.26-35.02)	2.82 (0.26-7.07)	5.51 (2.57-35.02)	3.73 (0.54-33.71)	1.53 (0.26-2.64)
Monocytes % CD45 <sup>+</sup> cells Median (range)	0.50 (0.08-14.72)	1.20 (0.08-14.06)	0.48 (0.14-3.08)	0.46 (0.15-14.72)	0.33 (0.16-2.72)
<b>cDCs</b> %CD45 <sup>+</sup> cells Median (range)	0.47 (0.01-4.55)	1.57 (0.01-4.55)	0.43 (0.01-2.66)	0.36 (0.23-2.07)	0.63 (0.43-1.14)

547 **Table 2.** Immune cell subtype frequency in bronchial brushings samples from children aged

548 0-15 years.

BRONCHIAL IMMUNE CELLS	0-15 years (n=17)	<b>0-5 years</b> (n=8)	<b>6-10 years</b> (n=5)	<b>11-15 years</b> (n=4)
Total granulocytes	40.84	58.86	18.34	33.53
%CD45 <sup>+</sup> cells	(1 85-89 57)	(5.04-89.57)	(1 85-56 76)	(15 00-47 54
Median (range)	(1.00 0).07)	(0.01 0).07)	(1.00 0.000)	(10100 1710)
Eosinophils	0.41	0.23	1.66	2.34
%CD45 <sup>+</sup> cells	(0.01 - 4.41)	(0.02 - 1.52)	(0.12 - 4.04)	(0.01-4.41)
Median (range)	(0.01)	(0.02 1.02)	(0112 110 1)	(0101 111)
Neutrophils	30.75	56.10	15.91	20.41
%CD45 <sup>+</sup> cells	(1.58-85.04)	(4.6 - 85.04)	(1.58-52.41)	(9.88-37.80
Median (range)	(1.00 00101)	(	(1100 02111)	().00 07100
Macrophages	3.46	1.47	3.53	9.03
%CD45 <sup>+</sup> cells	(0.68-11.56)	(0.68 - 3.71)	(3.09-10.74)	(3.62-11.56
Median (range)	(0.00 0)	(0.00 0	(0.03) - 0.0)	(2002-2002
NK cells	1.46	1.24	0.98	2.74
%CD45 <sup>+</sup> cells	(0.26-5.88)	(0.31 - 5.88)	(0.26 - 1.83)	(0.61-4.44
Median (range)	(0.200000)	(0.0 - 0.00)	(0.20 2.002)	(0.02
NK-T cells	0.98	0.33	1.70	2.60
%CD45 <sup>+</sup> cells	(0.07 - 6.56)	(0.07 - 2.05)	(0.16 - 2.65)	(0.78-6.56
Median (range)	` '	,	, ,	``
CD8 T cells	13.78	7.89	13.78	22.56
%CD45 <sup>+</sup> cells	(0.86 - 33.92)	(1.85 - 21.82)	(0.86 - 33.92)	(8.43-27.76
Median (range)	(11111)	(	( , , , , , , , , , , , , , , , , , , ,	
CD4 T cells	3.35	3.77	4.23	6.49
%CD45 <sup>+</sup> cells	(0.06-19.24)	(0.11 - 19.24)	(1.58-10.50)	(0.06-18.61
Median (range)	· · ·	· · · ·	· · · ·	``
B cells	2.10	2.54	1.86	1.87
%CD45 <sup>+</sup> cells	(0.29-12.61)	(0.5 - 5.35)	(0.29-12.26)	(0.67-12.61
Median (range)	````	· · · ·		, ,
Monocytes	1.27	1.53	1.59	0.73
%CD45 <sup>+</sup> cells	(0.01 - 15.58)	(0.08-15.58)	(0.31 - 5.95)	(0.01-1.39
Median (range)	· · · · · · · · · · · · · · · · · · ·	· · · · · · · · · · · · · · · · · · ·		
cDCs	0.70	0.73	0.70	0.87
%CD45 <sup>+</sup> cells	(0.01-2.11)	(0.01 - 2.11)	(0.04 - 1.59)	(0.01-1.52)
Median (range)				

550	Table 3.	Immune cel	l subtype	frequency	in	broncl	hoaly	veolar	lavage	(BAL	) samp	les f	rom
-----	----------	------------	-----------	-----------	----	--------	-------	--------	--------	------	--------	-------	-----

children aged 0-15 years.

ALVEOLAR IMMUNE CELLS	0-15 years (n=8)	<b>0-5 years</b> (n=5)	<b>6-10 years</b> (n=3)
Total granulocytes	1.88	1.59	2.16
%CD45 <sup>+</sup> cells	(0.49 - 8.48)	(0.49 - 8.49)	(0.53 - 3.51)
Median (range)	````	· · · ·	、
Eosinophils	0.06	0.10	0.03
%CD45 <sup>+</sup> cells	(0.003 - 0.20)	(0.01-0.20)	(0.02 - 0.10)
Median (range)	· · · ·	、	、
Neutrophils	1.82	1.5	2.13
%CD45 <sup>+</sup> cells	(0.49 - 8.33)	(0.49 - 8.33)	(0.50 - 3.40)
Median (range)			
Macrophages	80.05	78.5	84.37
%CD45 <sup>+</sup> cells	(58.77-87.01)	(58.77-83.60)	(73.82-87.01)
Median (range)			
NK cells	0.39	0.21	0.42
%CD45 <sup>+</sup> cells	(0.10-0.90)	(0.10-0.90)	(0.35 - 0.43)
Median (range)			
NK-T cells	0.19	0.13	0.54
%CD45 <sup>+</sup> cells	(0.02 - 0.63)	(0.02 - 0.23)	(0.32-0.63)
Median (range)			
CD8 T cells	3.87	4.11	3.62
%CD45 <sup>+</sup> cells	(0.35-10.96)	(0.35-10.96)	(3.5-6.54)
Median (range)			
CD4 T cells	3.42	3.49	2.64
%CD45 <sup>+</sup> cells	(0.01 - 8.78)	(0.01-6.45)	(2.38 - 8.78)
Median (range)	0 o <b>-</b>		0.10
B cells	0.97	1.25	0.69
%CD45 <sup>+</sup> cells	(0.16-5.09)	(0.37-5.09)	(0.16 - 1.55)
Median (range)	0.4.5	0.00	
Monocytes	0.46	0.99	0.20
%CD45 <sup>+</sup> cells	(0.15-2.41)	(0.15-2.41)	(0.19-0.38)
Median (range)	0	0.5.1	0.53
cDCs	0.65	0.94	0.52
%CD45 <sup>+</sup> cells	(0.10-1.61)	(0.10 - 1.61)	(0.37 - 0.78)
Median (range)			

552

553

# **Table 4.** Immune cell subtype frequency in tonsils from children aged 0-15 years.

TONSIL IMMUNE CELLS	0-15 years (n=31)	<b>0-2 years</b> (n=5)	<b>3-5 years</b> (n=13)	<b>6-10 years</b> (n=9)	<b>11-15 years</b> (n=4)
Neutrophils %CD45 <sup>+</sup> cells Median (range)	0.59 (0.05-2.36)	0.17 (0.06-1.29)	0.70 (0.05-1.52)	0.49 (0.19-1.18)	2.03 (1.34-2.36)
<b>Plasma blasts</b> %CD45 <sup>+</sup> cells Median (range)	1.38 (0.41-3.54)	1.53 (1.20-1.95)	1.33 (0.54-2.91)	1.60 (0.41-3.54)	1.32 (0.94-1.81)
GC B cells %CD45 <sup>+</sup> cells Median (range)	18.84 (7.16-42.73)	22.69 (7.16-42.73)	18.47 (9.64-30.00)	19.01 (9.31-27.40)	9.59 (7.25-24.30)
Atypical memory B cells %CD45 <sup>+</sup> cells Median (range)	3.62 (1.44-8.64)	2.19 (1.78-2.98)	4.42 (2.47-7.01)	3.62 (1.82-4.50)	2.79 (1.44-864)
<b>Classical memory B cells</b> %CD45 <sup>+</sup> cells Median (range)	1.63 (0.45-3.72)	0.53 (0.45-1.60)	1.80 (0.79-2.59)	1.47 (0.77-3.72)	2.77 (1.56-3.39)
Naïve B cells %CD45 <sup>+</sup> cells Median (range)	16.45 (4.44-36.15)	14.39 (9.73-29.40)	15.07 (9.93-19.94)	16.53 (4.44-29.87)	18.44 (17.06-36.15)
Non-switched memory B cells %CD45 <sup>+</sup> cells Median (range)	1.69 (0.61-7.88)	1.29 (0.74-1.92)	1.77 (0.87-3.99)	1.69 (0.61-7.88)	2.51 (1.30-2.77)
Plasma cells %CD45 <sup>+</sup> cells Median (range)	0.40 (0.02-1.96)	0.16 (0.03-1.31)	0.40 (0.04-1.96)	0.45 (0.15-0.64)	0.10 (0.02-0.70)
<b>Transitional B cells</b> %CD45 <sup>+</sup> cells Median (range)	10.27 (4.06-17.21)	14.81 (6.50-17.21)	11.33 (7.36-14.24)	8.76 (4.06-13.25)	5.90 (5.04-10.02)
NK cells %CD45 <sup>+</sup> cells Median (range)	0.37 (0.08-1.09)	0.37 (0.22-0.80)	0.37 (0.1-1.09)	0.37 (0.08-0.59)	0.37 (0.24-0.50)
NK-T cells %CD45 <sup>+</sup> cells Median (range)	0.09 (0.02-0.21)	0.07 (0.02-0.21)	0.09 (0.04-0.20)	0.11 (0.03-0.18)	0.05 (0.04-0.12)
<b>CD8 TCM</b> %CD45 <sup>+</sup> cells Median (range)	1.35 (0.2-4.34)	0.41 (0.20-1.38)	1.11 (0.33-4.34)	1.35 (0.46-3.11)	2.38 (1.94-2.81)
<b>CD8 TN</b> %CD45 <sup>+</sup> cells Median (range)	2.79 (0.94-9.54)	2.83 (1.6-9.54)	3.21 (1.51-7.71)	2.97 (1.43-8.29)	1.73 (0.94-2.79)
<b>CD8 TEMRA</b> %CD45 <sup>+</sup> cells Median (range)	0.23 (0.12-3.04)	0.22 (0.17-0.38)	0.26 (0.14-0.93)	0.20 (0.36-2.17)	0.19 (0.12-0.41)
<b>CD8 TEM</b> %CD45 <sup>+</sup> cells Median (range)	0.52 (0.13-3.01)	0.23 (0.14-0.33)	0.64 (0.13-2.13)	0.53 (0.36-2.17)	1.66 (0.52-3.01)
Activated Tregs %CD45 <sup>+</sup> cells Median (range)	0.55 (0.19-1.47)	0.41 (0.19-1.25)	0.54 (0.20-1.47)	0.57 (0.32-0.95)	0.35 (0.31-0.57)

Naive Tregs %CD45 <sup>+</sup> cells Median (range)	2.46 (1.13-5.75)	2.76 (1.95-3.10)	2.46 (1.56-5.75)	2.14 (1.43-4.78)	3.01 (1.13-3.62)
<b>TFH cells</b> %CD45 <sup>+</sup> cells Median (range)	8.57 (4.59-17.84)	8.49 (6.88-12.10)	8.87 (4.66-11.77)	8.56 (4.63-12.12)	7.20 (4.59-17.84)
<b>CD4 Thelper cells</b> %CD45 <sup>+</sup> cells Median (range)	9.19 (3.93-19.32)	7.60 (3.93-8.83)	8.78 (7.16-14.70)	12.10 (7.25-15.06)	13.75 (11.69-19.32)
<b>CD4 TN</b> %CD45 <sup>+</sup> cells Median (range)	6.07 (1.61-13.14)	5.65 (3.32-12.31)	6.07 (2.60-10.50)	6.65 (3.34-13.14)	4.35 (1.61-6.59)
<b>CD4 TEMRA</b> %CD45 <sup>+</sup> cells Median (range)	0.39 (0.11-2.15)	0.32 (0.21-0.89)	0.44 (0.17-1.59)	0.35 (0.19-2.15)	0.79 (0.11-1.28)
Monocytes %CD45 <sup>+</sup> cells Median (range)	0.40 (0.13-1.13)	0.22 (0.13-0.63)	0.47 (0.26-1.13)	0.28 (0.20-0.60)	0.41 (0.28-0.51)
<b>cDCs</b> %CD45 <sup>+</sup> cells Median (range)	0.17 (0.04-0.41)	0.16 (0.12-0.22)	0.16 (0.10-0.35)	0.18 (0.04-0.41)	0.17 (0.12-0.39)
<b>pDCs</b> %CD45 <sup>+</sup> cells Median (range)	0.32 (0.04-0.89)	0.26 (0.10-0.35)	0.35 (0.19-0.89)	0.28 (0.04-0.54)	0.15 (0.09-0.30)
ILCs %CD45 <sup>+</sup> cells Median (range)	0.32 (0.05-0.96)	0.39 (0.10-0.48)	0.48 (0.08-0.96)	0.31 (0.05-0.81)	0.45 (0.27-0.60)

# **Table 5.** Immune cell subtype frequency in adenoids from children aged 0-15 years.

ADENOID IMMUNE CELLS	0-15 years (n=36)	<b>0-2 years</b> (n=4)	<b>3-5 years</b> (n=14)	<b>6-10 years</b> (n=10)	<b>11-15 years</b> (n=8)
Neutrophils %CD45 <sup>+</sup> cells Median (range)	0.27 (0.07-3.47)	0.48 (0.21-0.88)	0.29 (0.11-2.83)	0.26 (0.08-0.40)	0.11 (0.07-3.47)
Plasma blasts %CD45 <sup>+</sup> cells Median (range)	0.89 (0.31-1.66)	0.83 (0.55-1.30)	1.02 (0.44-1.52)	0.68 (0.31-1.46)	0.90 (0.33-1.66)
GC B cells %CD45 <sup>+</sup> cells Median (range)	10.38 (1.76-32.58)	11.33 (8.88-16.06)	14.27 (9.15-32.58)	9.41 (4.31-21.51)	6.49 (1.76-19.93)
Atypical memory B cells %CD45 <sup>+</sup> cells Median (range)	3.85 (1.08-9.17)	2.27 (1.73-4.15)	4.59 (2.77-7.08)	3.51 (2.46-6.92)	3.87 (1.08-9.17)
Classical memory B cells % CD45 <sup>+</sup> cells Median (range)	2.80 (0.66-8.91)	0.98 (0.66-1.32)	2.88 (1.37-5.88)	3.25 (1.82-7.87)	3.14 (1.74-8.91)
Naïve B cells % CD45 <sup>+</sup> cells Median (range)	18.63 (8.30-43.75)	22.71 (11.05-27.67)	17.48 (11.78-36.03)	17.32 (8.30-26.74)	17.89 (11.17-43.75)
<b>Non-switched memory B cells</b> %CD45 <sup>+</sup> cells Median (range)	2.72 (0.89-6.63)	1.51 (0.89-2.17)	2.23 (1.37-2.86)	3.94 (1.14-6.63)	4.29 (2.53-5.64)
Plasma cells % CD45 <sup>+</sup> cells Median (range)	0.20 (0.03-0.77)	0.14 (0.12-0.25)	0.25 (0.03-0.77)	0.16 (0.04-0.63)	0.20 (0.10-0.57)
<b>Transitional B cells</b> %CD45 <sup>+</sup> cells Median (range)	9.48 (3.25-24.75)	14.51 (11.22-24.75)	10.92 (3.25-12.71)	8.06 (5.08-13.53)	6.28 (3.52-16.21)
NK cells %CD45 <sup>+</sup> cells Median (range)	0.63 (0.25-1.58)	0.57 (0.42-1.58)	0.77 (0.38-1.26)	0.63 (0.25-1.34)	0.64 (0.35-1.24)
NK-T cells %CD45 <sup>+</sup> cells Median (range)	0.09 (0.02-0.52)	0.06 (0.03-0.07)	0.08 (0.02-0.52)	0.11 (0.05-0.19)	0.14 (0.08-0.23)
<b>CD8 TCM</b> %CD45 <sup>+</sup> cells Median (range)	0.92 (0.22-3.38)	0.46 (0.31-0.60)	0.92 (0.23-3.10)	1.14 (0.22-3.14)	1.90 (0.50-3.38)
CD8 TN %CD45 <sup>+</sup> cells Median (range)	3.37 (0.62-9.69)	5.19 (3.23-8.21)	2.65 (1.75-7.42)	3.32 (1.53-5.90)	3.75 (0.62-9.69)
<b>CD8 TEMRA</b> %CD45 <sup>+</sup> cells Median (range)	0.36 (0.11-2.34)	0.47 (0.2-1.12)	0.33 (0.14-0.79)	0.48 (0.20-1.57)	0.20 (0.11-2.34)
<b>CD8 TEM</b> %CD45 <sup>+</sup> cells Median (range)	0.83 (0.17-3.13)	0.38 (0.17-0.84)	0.58 (0.27-1.62)	0.92 (0.39-2.88)	1.14 (0.65-3.13)
Activated Tregs %CD45 <sup>+</sup> cells Median (range)	0.56 (0.13-1.74)	0.50 (0.27-0.71) 24	0.49 (0.20-1.13)	0.62 (0.22-1.74)	0.57 (0.13-1.10)

2.62	2.24	2.73	3.21	2.60
(0.91-7.12)	(1.31-3.11)	(1.37-5.33)	(1.31-7.12)	(0.91-3.45)
9.84	10.95	10.74	9.80	7.34
(0.50-17.32)	(8.32-17.32)	(4.59-14.71)	(4.64-13.24)	(0.50-14.33)
11.90	6.51	8.81	15.18	16.78
(1.90-26.26)	(4.96-9.12)	(1.90-13.39)	(7.94-19.69)	(6.37-26.26)
5.58	6.83	4.69	6.41	5.57
(0.86-16.73)	(5.06-12.27)	(3.19-8.66)	(3.66-9.59)	(0.86-16.73)
0.46	0.48	0.51	0.44	0.56
(0.07-1.20)	(0.23-0.75)	(0.23-1.06)	(0.21-1.20)	(0.07-0.94)
0.36	0.45	0.46	0.34	0.34
(0.14-1.08)	(0.21-0.58)	(0.21-0.86)	(0.16-1.08)	(0.14-0.99)
0.23	0.19	0.21	0.26	0.24
(0.09-0.87)	(0.17-0.25)	(0.09-0.87)	(0.12-0.58)	(0.14-0.50)
0.83	0.51	0.98	0.68	1.04
(0.13-2.98)	(0.42-1.59)	(0.29-2.07)	(0.35-1.64)	(0.13-2.98)
0.34	0.32	0.33	0.44	0.33
(0.01-1.24)	(0.26-0.38)	(0.10-1.24)	(0.07-0.64)	(0.01-0.85)
	$\begin{array}{c} 2.62\\ (0.91-7.12)\\ \hline 9.84\\ (0.50-17.32)\\ \hline 11.90\\ (1.90-26.26)\\ \hline 5.58\\ (0.86-16.73)\\ \hline 0.46\\ (0.07-1.20)\\ \hline 0.36\\ (0.14-1.08)\\ \hline 0.23\\ (0.09-0.87)\\ \hline 0.83\\ (0.13-2.98)\\ \hline 0.34\\ (0.01-1.24)\\ \end{array}$	2.62 $(0.91-7.12)$ $2.24$ $(1.31-3.11)$ $9.84$ $(0.50-17.32)$ $10.95$ $(8.32-17.32)$ $11.90$ $(1.90-26.26)$ $6.51$ $(4.96-9.12)$ $5.58$ $(0.86-16.73)$ $6.83$ $(5.06-12.27)$ $0.46$ $(0.07-1.20)$ $0.48$ $(0.23-0.75)$ $0.36$ $(0.14-1.08)$ $0.45$ $(0.21-0.58)$ $0.23$ $(0.09-0.87)$ $0.19$ $(0.42-1.59)$ $0.34$ $(0.01-1.24)$ $0.32$ $(0.26-0.38)$	2.62 $(0.91-7.12)$ $2.24$ $(1.31-3.11)$ $2.73$ $(1.37-5.33)$ $9.84$ $(0.50-17.32)$ $10.95$ $(8.32-17.32)$ $10.74$ $(4.59-14.71)$ $11.90$ $(1.90-26.26)$ $6.51$ $(4.96-9.12)$ $8.81$ $(1.90-13.39)$ $5.58$ $(0.86-16.73)$ $6.83$ $(5.06-12.27)$ $4.69$ $(3.19-8.66)$ $0.46$ $(0.07-1.20)$ $0.48$ $(0.23-0.75)$ $0.51$ $(0.23-1.06)$ $0.36$ $(0.14-1.08)$ $0.45$ $(0.21-0.58)$ $0.46$ $(0.21-0.86)$ $0.23$ $(0.09-0.87)$ $0.19$ $(0.17-0.25)$ $0.98$ $(0.29-2.07)$ $0.34$ $(0.01-1.24)$ $0.32$ $(0.26-0.38)$ $0.33$ $(0.10-1.24)$	2.62 $(0.91-7.12)$ $2.24$ $(1.31-3.11)$ $2.73$ $(1.37-5.33)$ $3.21$ $(1.31-7.12)$ $9.84$ $(0.50-17.32)$ $10.95$ $(8.32-17.32)$ $10.74$ $(4.59-14.71)$ $9.80$ $(4.64-13.24)$ $11.90$ $(1.90-26.26)$ $6.51$ $(4.96-9.12)$ $8.81$ $(1.90-13.39)$ $15.18$ $(7.94-19.69)$ $5.58$ $(0.86-16.73)$ $6.83$ $(5.06-12.27)$ $4.69$ $(3.19-8.66)$ $6.41$ $(3.66-9.59)$ $0.46$ $(0.07-1.20)$ $0.48$ $(0.23-0.75)$ $0.51$ $(0.23-1.06)$ $0.44$ $(0.21-1.20)$ $0.36$ $(0.14+1.08)$ $0.45$ $(0.21-0.58)$ $0.46$ $(0.21-0.86)$ $0.26$ $(0.12-0.58)$ $0.33$ $(0.13-2.98)$ $0.51$ $(0.26-0.38)$ $0.98$ $(0.10-1.24)$ $0.68$ $(0.32-0.76)$

558	Table 6. Immune cell subtype frequency in whole blood samples from children aged 0-15
559	years.

WHOLE BLOOD IMMUNE CELLS	0-15 years (n=49)	<b>0-2 years</b> (n=6)	<b>3-5 years</b> (n=17)	<b>6-10 years</b> (n=15)	<b>11-15 years</b> (n=11)
Eosinophils					
%CD45 <sup>+</sup> cells	0.83	0.79	0.60	1.53	1.52
Median (range)	(0.04-11.98)	(0.29-2.28)	(0.04-6.55)	(0.17-11.98)	(0.13-5.95)
Neutrophils % CD45 <sup>+</sup> colls	27.50	25 52	21.80	30.68	38 30
Median (range)	(953-7772)	(13 34-75 76)	(953-3450)	$(14\ 75\ 77\ 72)$	(26 66-54 78)
Plasma blasts	().55 11.12)	(15.54 75.70)	().55 54.50)	(14.75 77.72)	(20.00 54.70)
%CD45 <sup>+</sup> cells	0.14	0.23	0.18	0.07	0.06
Median (range)	(0.01-0.68)	(0.04-0.58)	(0.09-0.68)	(0.01-0.47)	(0.02-0.37)
Atypical memory B cells					
%CD45 <sup>+</sup> cells	0.56	0.34	0.61	0.55	0.47
Median (range)	(0.17-1.71)	(0.29-0.40)	(0.40-1.33)	(0.17-1.51)	(0.22-1.71)
Classical memory B cells	0.52	0.25	0.74	0.55	0.45
%CD45 <sup>°</sup> cells Madian (ranga)	0.52	0.25	0./4	0.55	0.45
Nevro B colls	(0.11-1.90)	(0.11-0.52)	(0.19-1.09)	(0.14-1.90)	(0.25-1.09)
%CD45 <sup>+</sup> cells	674	7 18	7 32	5 73	612
Median (range)	(1 16 - 13 06)	(1 27-11 92)	(4 60-13 06)	(1 16-8 42)	(3.78-10.77)
Non-switched memory B cells	(1110 15:00)	(1.2, 11., 2)	(1.00 15.00)	(1.10 0.12)	(5.76 10.77)
%CD45 <sup>+</sup> cells	0.78	0.59	0.92	0.76	0.57
Median (range)	(0.19-2.68)	(0.19-0.88)	(0.21-2.68)	(0.32-1.60)	(0.19-1.44)
Plasma cells	0.00	0.11	0.17	0.09	0.07
%CD45' cells	(0.09)	(0.02.0.25)	0.1/	0.08	0.07
Transitional R calls	(0.01-1.79)	(0.05-0.55)	(0.04-0.03)	(0.01-1.79)	(0.01-0.80)
%CD45 <sup>+</sup> cells	1.53	2.43	2.06	0.96	1.09
Median (range)	(0.19-6.68)	(0.70-6.68)	(0.63-5.49)	(0.19-2.53)	(0.50-2.07)
CD16-CD56bright NK cells		(1111)	(1) 1 1 1 1		(
%CD45 <sup>+</sup> cells	0.31	0.43	0.31	0.33	0.19
Median (range)	(0.01-1.04)	(0.06-0.84)	(0.03-0.92)	(0.01-1.04)	(0.01-0.47)
CD16+CD56bright NK cells	0.10	0.07	0.15	0.07	0.08
Median (range)	(0.01-0.38)	(0.04-0.38)	(0.01-0.41)	(0.01-0.25)	$(0.00 \ (0.01 \ -0.37)$
CD16+CD56+ NK cells			(0.01 0.11)	(0.01 0.20)	(0.01 0.07)
%CD45 <sup>+</sup> cells	5.29	5.20	5.52	5.48	3.19
Median (range)	(0.01-18.38)	(0.21-9.10)	(0.01-13.72)	(1.72-12.74)	(0.01-18.38)
CD16-CD56+ NK cells	0.26	0.29	0.26	0.26	0.25
%CD45 <sup>°</sup> cells	(0.07, 1.00)	(0.07.0.70)	(0.20, 1.40)	(0.001.00)	(0.15, 1.17)
NK-T cells	(0.07-1.90)	(0.07-0.70)	(0.20-1.40)	(0.09-1.90)	(0.13-1.17)
%CD45 <sup>+</sup> cells	1.08	0.27	1.11	0.80	1.47
Median (range)	(0.19-3.22)	(0.20-0.32)	(0.40-2.98)	(0.19-2.86)	(0.37-3.22)
CD8 TCM	(	(	(	(	()
%CD45 <sup>+</sup> cells	0.81	0.65	0.82	1.05	0.81
Median (range)	(0.01-6.44)	(0.01-1.06)	(0.21-6.44)	(0.17-3.30)	(0.43 - 2.34)

CD8 TN %CD45 <sup>+</sup> cells	7.31	10.05	8.89	8.06	6.49
Median (range)	(0.04-19.47)	(0.04-13.60)	(3.38-19.47)	(1.36-13.11)	(1.97-9.57)
CD8 TEMRA		(111)	(	(	( ) )
%CD45 <sup>+</sup> cells	1.45	0.61	2.56	1.30	1.39
Median (range)	(0.01-5.85)	(0.01 - 3.70)	(0.63-5.85)	(0.30-2.40)	(0.42 - 2.90)
CD8 TEM					
%CD45 <sup>+</sup> cells	1.96	0.89	1.95	1.90	2.73
Median (range)	(0.02-26.52)	(0.01-2.15)	(0.40-26.52)	(0.23-4.35)	(1.06-5.01)
Activated Tregs					
%CD45 <sup>+</sup> cells	1.06	1.47	1.38	1.05	0.77
Median (range)	(0.01-2.81)	(0.03-1.98)	(0.72-2.59)	(0.01-2.81)	(0.38-1.49)
Naive Tregs					
%CD45 <sup>+</sup> cells	0.99	0.93	0.94	1.14	0.86
Median (range)	(0.02-3.73)	(0.02-1.45)	(0.34-1.54)	(0.12-3.73)	(0.44-2.36)
TFH cells					
%CD45 <sup>+</sup> cells	1.53	1.37	1.76	1.21	1.50
Median (range)	(0.03-9.72)	(0.03-2.0)	(0.31-9.72)	(0.35 - 2.49)	(0.96-6.41)
CD4 Thelper cells					
%CD45 <sup>+</sup> cells	4.51	3.66	3.82	4.96	6.28
Median (range)	(0.16-10.78)	(0.16-5.59)	(1.40-9.30)	(0.47-9.38)	(2.22-10.78)
CD4 TN		10.00		10.05	
%CD45 <sup>+</sup> cells	13.82	18.83	16.47	13.25	9.56
Median (range)	(0.27-31.01)	(0.35-31.01)	(7.15-26.00)	(0.27-22.06)	(5.70-24.11)
CD4 TEMRA	0.44	0.07	0.50	0.00	0.44
%CD45 <sup>°</sup> cells	0.41	0.37	0.52	0.30	0.41
Median (range)	(0.01-1.44)	(0.01-0.61)	(0.09-1.44)	(0.02-1.19)	(0.04-0.70)
cDCs	0.14	0.10	0.17	0.12	0.07
%CD45 <sup>°</sup> cells	0.14	0.19	0.1/	0.13	0.07
Median (range)	(0.02-0.66)	(0.04-0.49)	(0.04-0.66)	(0.02-0.40)	(0.02-0.21)
pDCs	0.00	0.12	0.10	0.07	0.05
%CD45 cells	0.09	0.13	(0.02, 0.22)	(0.01, 0.20)	(0.03)
Median (range)	(0.01-0.29)	(0.06-0.22)	(0.03-0.22)	(0.01-0.29)	(0.02-020)
Non-classical monocytes	0.22	0.22	0.27	0.22	0.11
%CD45 cells Modion (rongo)	(0.22)	(0.25)	(0.01.1.56)	(0.02, 0.72)	(0.01.0.66)
	(0.01-2.01)	(0.10-2.01)	(0.01-1.30)	(0.03-0.73)	(0.01-0.00)
<sup>9</sup> CD45 <sup>+</sup> colls	0.18	0.43	0.21	0.12	0.13
Median (range)	(0.01, 2.00)	(0.14.200)	(0.01, 1.61)	(0.02.0.26)	(0.01, 0.05)
Classical managettag	(0.01 - 2.99)	(0.14-2.99)	(0.01 - 1.01)	(0.05-0.50)	(0.01-0.93)
%CD45 <sup>+</sup> cells	1.85	3.04	1 68	1 72	1 90
Median (range)	(0.44 - 10.80)	(0.92 10.80)	(0.44-4.64)	(0.74.2.98)	(0.87.4.00)
II Ce	(0.77-10.00)	(0.72-10.00)	(0.77-7.04)	(0.77-2.90)	(0.07-4.00)
% CD45 <sup>+</sup> cells	0.83	0.69	0.94	1 09	0.71
Median (range)	(0.04-2.40)	(0.04 - 1.35)	$(0.36 \cdot 1.67)$	(0.24.2.40)	(0.26-1.90)
	(0.01-2.40)	(0.0+-1.55)	(0.50.1.07)	(0.2+2.+0)	$(0.20^{-1.90})$

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.



Figure 1



Figure 2









Figure 6